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Methods: A mixed culture of a wild-type ceftazidime/cefepime-susceptible ( 4 x  lo7 CFU/mL) strain and an ampC 
derepressed Enterobacter cloacae (lo5 CFU/mL) strain (relative proportions 99.75% and 0.25%) was challenged for 4 h 
with different antibiotic concentrations of ceftazidime and cefepime (0.03-4096 mg/L), and then transferred to  drug-free 
medium. The proportion of wild-type versus derepressed population was evaluated after 24 h. 
Results: Ceftazidime and cefepime selected the derepressed variant at concentrations ranging from 1 to  4096 and from 
0.12 to  16 mg/L respectively. 
Conclusions: These results suggest that serum concentrations attainable with a 2 g/8 h cefepime dosage may be able 
to  suppress the emergence of derepressed ampC mutants 
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One of the major problems in current p-lactam therapy 
is the emergence of high-level resistance Enterobacter 
variants during therapy with third-generation 
cephalosporins [1,2]. This type of mutant, frequently 
carrying an ampD mutation [3] ,  is generally present in 
the original population at a relatively high level, 
to lo-’. Antibiotics such as cefotaxime or ceftazidime 
are efficiently hydrolyzed by the AmpC enzyme, and 
this is why constitutive hyperproducer variants were 
able to resist high concentrations of these drugs, and 
therefore are selected (‘emerge’) during therapy. The 
major theoretical advantage of some new cephalosporin 
derivatives, such as cefepime, is the reduced AmpC 
enzyme affinity for these compounds. Because of that, 
the variant hyperproducer population is not expected 
to be efficiently selected [4]. 
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Theoretically, the selection of antibiotic-resistant 
variants should occur at particular selective antibiotic 
concentrations (SACS) [5,6], defined as the concentra- 
tions inhibiting the susceptible population but not the 
resistant variants. From the clinical point of view, it is 
appropriate to know the antibiotic concentrations at 
which the resistant variants are expected to be selected, 
in order to avoid as much as possible the maintenance 
of these concentrations in the infected site, and thus to 
prevent the emergence of resistance during treatment. 
In this paper an in vitro modeling procedure, which 
involves the building up of bacterial populations after a 
limited challenge with different antibiotic concentra- 
tions, is proposed. 
MATERIALS AND METHODS 
Strains 
The strain Enterobacter cloacae RYC12991, a clinical 
isolate, was used as a ‘susceptible’ strain. The strain 
had the following MICs, as determined by conven- 
tional methods: ceftazidime 0.5 mg/L, and cefepime 
0.5 mg/L [7] .  A nalidixic acid-resistant variant strain 
(MIC >64 mg/L) was obtained by one-step selection 
on plates containing 50 mg/L of nalidixic acid; the 
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strain was named KYC12991-Wrq. A ceftazidinie- 
resistant variant strain (ceftazidime MIC, 1024 mg/L; 
cefepime MIC, 16 nig/L) was obtained by seeding a 
den5e inoculum of RYC12991 on plates containing 
200 mg/L of ceftazidime. This strain hyperproduced 
(> lo0  000 U / m g  of protein) a PI 7.8 AmpC-type 
P-lactamase, and was named RYC12991-D. 
Fitness analysis 
In  order to calculate the eventual disadvantage that the 
mutant hyperproducer P-lactamase strain may have 
when competing with the wild-type strain ('cost' of 
antibiotic resistance), both populations were mixed 
at identical density (7x104/mL), seeded on 5 mL 
Mueller-Hinton (MH) broth, and incubated over- 
night. Immediately after the mixture was prepared, and 
after overnight incubation, non-antibiotic-containing 
M H  plates were seeded, and 100 colonies were studied 
on nalidixic acid agar plates and control plates, to 
calculate the proportion of each strain after incubation. 
A new 5-mL tube was inoculated with the overnight 
culture, and the same procedure was repeated for 6 
days. The final proportions of RYC12991-Wrq and 
KYCl2991-1> were established after this time by seeding 
on non-antibiotic- and nalidixic acid-containing agar 
plates. Experiments were carried out in triplicate. 
Selection of the resistant population 
A mixture was prepared with exponential M H  broth 
cultures of RYC12991-Wrq and RYC12991-El in the 
following proportions: 4 x lo7 and 1 x 10' CFU/mL 
(99.75% and 0.25% respectively). MH 5-mL tubes 
containing ceftazidime or cefepime (range 0.03- 
4096 mg/L) were seeded with the mixture, and 
incubated for 4 h at 37°C; aliquots from each tube were 
then transferred to drug-free MH broth tubes. After 
overnight incubation, dilutions of each tube were 
seeded in MH agar plates without antibiotic. After 
I8 h, 100 isolated colonies selected a t  random from 
each plate were spotted onto M H  control plates and on 
M H  plates containing 50 mg/L of nalidixic acid. 
Nalidixic acid-resistant spots obtained from antibiotic 
concentrations over 1 mg/L of ceftazidime or 
0.12 mg/L of cefepime were controlled for ceftazidime 
susceptibility after a week of daily passages in drug-free 
medium. in order to detect a reversible phenotype of 
an induced RYC12991-Wrq strain. All experiments 
were done at least in duplicate. 
RESULTS 
Fitness analysis 
I n  the absence of antibiotic selection, the resistant strain 
RYC12991 -D had a strong disadvantage in replication 
rate if coinpared with the wild strain. After overnight 
culture, the proportion of this resistant strain dropped 
from 58% to 19%). Not a single colony of this resistant 
strain was recovered among 100 colonies analyzed 
after 6 days of co-cultivation with the susceptible 
population. 
Selection of derepressed population in mixed cultures 
Under our experimental conditions, the susceptible E.  
clo'icae RYCl2991-Wrq strain began to lose represent- 
ation in 24-h populations resulting from mixed inocula 
challenged for 4 h with a ceftazidime concentration of 
1 mg/L. A very sharp decrease in the original propor- 
tion occurred after a challenge of 2 mg/L, with a heavy 
selection of the resistant mutant, which reached more 
than 90% of the total population. In concentrations 
ranging from 4 to 256 nig/L, a small percentage of the 
susceptible KYC12991-Wrq strain remained in the 
total population. All nalidixic acid-resistant colonies 
isolated from the 4-256 mg/L cultures regained total 
susceptibility to ceftazidime or cefepime after passage 
in drug-free medium. Above a concentration of 
254 mg/L of ceftazidime, all colonies corresponded to 
the derepressed variant (Figure 1). Therefore, the 
theoretical selective concentrations interval (the 
'selective window') for ceftazidime was in our CdSe 1 to 
>4096 mg/L. It is expected that any concentration in 
this range will be strongly selective for the hyper- 
producer variant strain. 
In the case of cefepime, the susceptible E.  cloacae 
RYC12991-Wrq population sharply disappeared in a 
sample of 100 colonies of the 24-h population after the 
4-h treatment of the mixture with only 0.12 mg/L, and 
the same effect was obtained with higher concentra- 
tions. As expected, the RYC12991-D strain appeared 
as the predominant population (more than 98%) in 24- 
h cultures obtained after challenge with 0.12 mg/L for 
4 h. After a challenge of 0.12-16 mg/L of cefepime, 
the RYC12991 -D strain constituted more than 97?4 
of the recovered colonies (Figure 1 ) .  In populations 
challenged with 0.12-4 mg/L, a small proportion o i  
induced RYC12291 -Wrq was detected. Interestingly. 
no growth was obtained with a challenge of over 
16 mg/L of cefepime. Thus, in our  experimentdl 
conditions, the cefepime selective concentrations 
interval for the hyperproducer variant was 
0.12-16 ntg/L. 
Serum pharmacokinetics and selective windows for 
ceftazidime and cefepime 
Ceftazidime and cefepime have very ~iiriilar pharma- 
cokmetic parameters, with C,,,,, values of about 180 
and 130 mg/L after a 2000-mg intravenous dose (the 
concentrations are roughly proportional to the dose), 
and t values of 1 8 and 2 1 h respectively For the case 
of the E cloacae model 3tudied in this work, and after 
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Figure 1 Proportion of wild-type E. cloacae RYC12991 strain (white bars), and constitutively derepressed variants 
hyperproducing AmpC (black bars), after a 4-h challenge with different concentrations of ceftazidime (upper part) or 
cefepime (lower part), followed by it 24-h period of growth in antibiotic-free medium. 
a single 2-g intravenous dose, c’eftazidime is expected 
to achieve selective concentrations almost immediately, 
and these concentrations wdl be maintained for 13.8 h 
(Figure 2). O n  the contrary, after 2 g of intravenous 
cefepime, there is a period of 7.4 h above the selective 
concentrations; then, the curve enters into the selective 
area for 13.8 h (Figure 2). With a 1-g dose, ceftazidime 
reduces the immediate selective time from 13.8 to 
11.8 h. In the case of cefepime, the reduction of the 
dose from 2 to 1 g is expected tlD decrease from 7.4 to 
5.4 h the selective-free period after injection. Within 1 
day, the length of the selective period does not 
significantly change for 1- or 2-g cefepime doses, being 
nearly 13.7 h in all cases. 
In many cases, what are incorrectly called ‘rates of 
mutation’ are in fact ‘rates of selection’ of the different 
antibiotics, depending on their intrinsic activity on the 
mutant subpopulation, or, in other words, on the 
differential activity on wild (susceptible) and mutant 
(resistant) populations. In most cases, this differential 
activity is reflected by a new ‘proportion’ of susceptible 
and resistant strains in populations resulting from 
growth of the surviving cells after antibiotic challenge 
[5]. This differential activity, considered together with 
the expected antibiotic concentrations in the human 
body at different times, expresses the ‘selective window’ 
of concentrations for each antibiotic (Figure 2). 
The model studied here predicts that in the case of 
ceftazidime 1 or 2 g every 8 or 12 h, a continuous 
selective window for resistant Enterobacter variants 
should occur. O n  the contrary, in the case of cefepime, 
the model suggests that a therapeutic schedule based on 
the intravenous administration of 2 g every 8 h should 
be only weakly selective for derepressed Enterobacter 
mutants. This schedule should produce three very 
short selective periods of 0.6 h/day, the blood levels 
being maintained over the concentration selecting 
RYC12991-D during 22.2 h/day. Nevertheless, with a 
12-h schedule, two selective windows of 4.6 h may 
occur every 24 h, during which selection of resistant 
Enterobacter is expected to occur. In the case of a 
schedule based on 1 g cefepime every 8 h, three 
selective periods of 2.6 h/day can be predicted. With 
1 g every 12 h, two 6.6-h selective periods per day are 
expected. In summary, according to this model, the 
potential advantage of cefepime over ceftazidime is 
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Figure 2 Expected serum lev& of ceftazidime (A) or  cefepinle (W) after a single intravenous administration of 1 g (A) or  
2 g (B). T h e  frames show the time periods where the concentrations may be Telective for the constitutively AmpC p- 
lactaniase hyperproducer E. rloarae RYC12991 strain. 
based on its s h o r t e r  risk period f o r  se lec t ion  of 
derepressed Eiztevobacter mutants .  T h i s  advantage  is 
ev ident  w i t h  a 2-g dosage  a n d  par t icular ly  i m p o r t a n t  in 
a three  t imes  a day schedule .  I n  t h e  case of t h e  presence  
of derepressed mutants  tha t  were selected by cefepime 
8 mg/L (instead of 16 mg/L as in our m o d e l ) ,  
in t ravenous  adminis t ra t ion  of 2 g/8 h is expected t o  
comple te ly  suppress  t h e  e m e r g e n c e  of t h e  resistant 
popula t ion .  S tudies  focused  on u n d e r s t a n d i n g  t h e  
mechanisms of select ion of bacter ia l  resistant popula-  
t ions  a c c o r d i n g  t o  t h e  pharmacokine t ics  of t h e  
ant ibiot ics  with different dosage pa t te rns  a r e  urgent ly  
required.  
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